DMA trihydrochloride
目录号 : GC34098
A radioprotective agent
Cas No.:2095832-33-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
DMA is a bisbenzimidazole radioprotective agent.1,2 In vivo, DMA (300 mg/kg) decreases radiation-induced lethality without affecting radiation-induced tumor regression in an Ehrlich murine spontaneous adenocarcinoma model.1 It prevents radiation-induced damage of intestinal, hepatic, and splenic tissues, increases in splenic malondialdehyde (MDA) production, and decreases in splenic superoxide dismutase (SOD) activity in a B16/F10 murine melanoma model when administered at a dose of 50 mg/kg.2
1.Nimesh, H., Tiwari, V., Yang, C., et al.Preclinical evaluation of DMA, a bisbenzimidazole, as radioprotector: Toxicity, pharmacokinetics, and biodistribution studies in Balb/c miceMol. Pharmacol.88(4)768-778(2015) 2.Tiwari, V., Kamran, M.Z., Ranan, A., et al.Akt1/NFκB signaling pathway activation by a small molecule DMA confers radioprotection to intestinal epithelium in xenograft modelFree Rad. Biol. Med.108564-574(2017)
Cell experiment: | Various human tumor cells (U87, HeLa and MCF7) are maintained as monolayer at 37°C in 5% CO2 using DMEM medium. Approximately 3000-8000 cells/well are seeded in 96-well plates containing 200 μL of medium and incubated for 24 h. The culture medium is replaced by fresh medium containing 1, 10, 50, 100 μM of DMA (6c) and incubated for 24, 48 and 72 h. The cell viability is determined by the MTT assay. The light absorbance is measured using a microplate reader[1]. |
References: [1]. Singh M, et al. Synthesis and biological activity of novel inhibitors of topoisomerase I: 2-aryl-substituted 2-bis-1H-benzimidazoles. Eur J Med Chem. 2011 Feb;46(2):659-69. | |
| Cas No. | 2095832-33-8 | SDF | |
| Canonical SMILES | CN1CCN(C2=CC=C3C(N=C(C4=CC=C5C(N=C(C6=CC=C(OC)C(OC)=C6)N5)=C4)N3)=C2)CC1.[H]Cl.[H]Cl.[H]Cl | ||
| 分子式 | C27H31Cl3N6O2 | 分子量 | 577.93 |
| 溶解度 | Water : 15.9 mg/mL (27.51 mM) | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7303 mL | 8.6516 mL | 17.3031 mL |
| 5 mM | 0.3461 mL | 1.7303 mL | 3.4606 mL |
| 10 mM | 0.173 mL | 0.8652 mL | 1.7303 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet